[Federal Register Volume 78, Number 136 (Tuesday, July 16, 2013)]
[Notices]
[Pages 42527-42528]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2013-16947]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 209 and 37 CFR part 404 to achieve expeditious
commercialization of results of federally-funded research and
development. Foreign patent applications are filed on selected
inventions to extend market coverage for companies and may also be
available for licensing.
FOR FURTHER INFORMATION CONTACT: Licensing information and copies of
the U.S. patent applications listed below may be obtained by writing to
the indicated licensing contact at the Office of Technology Transfer,
National Institutes of Health, 6011 Executive Boulevard, Suite 325,
Rockville, Maryland 20852-3804; telephone: 301-496-7057; fax: 301-402-
0220. A signed Confidential Disclosure Agreement will be required to
receive copies of patent applications.
Islet Beta Cell Only M3 Muscarinic Acetylcholine Receptor Knockout
Mouse
Description of Technology: Researchers at NIH have developed islet
beta cell M3 muscarinic acetylcholine receptor knockout mouse. The mice
were generated by crossing floxed mouse M3 muscarinic acetylcholine
receptor mice with mice in which Cre recombinase was controlled by the
beta-cell specific rat insulin promoter (RIP-Cre mice).
Potential Commercial Applications: Study of the physiological role
of beta-cell M3 muscarinic receptors in the regulation of glucose
homeostasis and insulin release in vivo.
Competitive Advantages: Allows for study of the role of the M3
receptors in the pancreas without whole body effects confounding the
results.
Development Stage: In vivo data available (animal)
Inventor: J[uuml]rgen Wess, Ph.D. (NIDDK)
Publication: Gautam D, et al. A critical role for beta cell M3
muscarinic acetylcholine receptors in regulating insulin release and
blood glucose homeostasis in vivo. Cell Metab. 2006 Jun;3(6):449-61.
[PMID 16753580]
Intellectual Property: HHS Reference No. E-452-2013/0--Research
Tool. Patent protection is not being pursued for this technology.
Licensing Contact: Jaime M. Greene, M.S.; 301-435-5559;
[email protected].
Transgenic Mice With Constitutively Active M3 Muscarinic Receptor in
Islet Beta Cells
Description of Technology: Q490L point mutation was introduced into
the rat M3 muscarinic receptor cDNA to confer persistent, constitutive
(ligand-independent) activity. Expression of the M3 receptor mutant was
placed under the control of a 650 bp fragment of the rat insulin
promoter II (RIP II) to limit expression to the islet beta cell.
Potential Commercial Applications: Diabetes research, especially
type II Diabetes.
Competitive Advantages: Beneficial metabolic effects of this mouse
model include high basal insulin secretion, improved glucose tolerance,
increased serum insulin, and resistance to high-fat diet-induced
glucose intolerance and hyperglycemia.
Development Stage: In vivo data available (animal)
Inventor: J[uuml]rgen Wess, Ph.D. (NIDDK)
Publication: Gautam D, et al. Beneficial metabolic effects caused
by persistent activation of beta-cell M3 muscarinic acetylcholine
receptors in transgenic mice. Endocrinology. 2010 Nov;151(11):5185-94.
[PMID 20843999]
Intellectual Property: HHS Reference No. E-453-2013/0--Research
Tool. Patent protection is not being pursued for this technology.
Licensing Contact: Jaime M. Greene, M.S.; 301-435-5559;
[email protected].
Transgenic Mice Overexpressing Islet Beta Cell M3 Muscarinic
Acetylcholine Receptors
Description of Technology: Researchers at NIH have generated
transgenic mice in which the M3 muscarinic receptor is overexpressed in
pancreatic beta cells. This was done by placing the receptor gene under
the control of the 650 bp rat insulin promoter II (RIP II). The
resulting mice show a pronounced increase in glucose tolerance and
enhanced plasma insulin levels. Strikingly, these mutant mice were
resistant to diet-induced glucose intolerance and hyperglycemia.
Potential Commercial Applications: Diabetes research, especially
type II Diabetes.
Competitive Advantages: These transgenic mice overexpress the M3
muscarinic acetylcholine receptor only in pancreatic beta cells but
notably are resistant to diet-induced glucose intolerance and
hyperglycemia.
Development Stage: In vivo data available (animal).
Inventor: J[uuml]rgen Wess, Ph.D. (NIDDK).
Publication: Gautam D, et al. A critical role for beta cell M3
muscarinic acetylcholine receptors in regulating insulin release and
blood glucose homeostasis in vivo. Cell Metab. 2006 Jun;3(6):449-61.
[PMID 16753580].
Intellectual Property: HHS Reference No. E-455-2013/0--Research
Tool. Patent protection is not being pursued for this technology.
Licensing Contact: Jaime M. Greene, M.S.; 301-435-5559;
[email protected].
An Improved System for Production of Recombinant Baculovirus
Description of Technology: Baculoviruses have been used for decades
to produce proteins in insect cell hosts. Current systems for
generating recombinant baculovirus have several shortcomings which
prevent their easy use in high-throughput applications. The present
[[Page 42528]]
invention discloses an improved system to quickly and efficiently
generate recombinant baculoviruses which produce recombinant proteins.
In the new system, the baculovirus transfer vector, transposition
helper plasmid and E. coli strain carrying the bacmid DNA were modified
to eliminate the need for screening positive clones and improve the
efficiency of baculovirus production. Taken together, these
improvements permit facile high-throughput recombinant baculovirus
production at reduced cost and improved speed over the currently
available systems.
Potential Commercial Applications:
High-throughput protein production
Generation of virus-like particles in insect cells
Competitive Advantages:
Elimination of background plasmid DNA during recombinant
baculovirus production
Elimination of nonproductive transposition events leading
to false positives
Lower cost production of baculovirus
Increased speed of baculovirus production (allowing high-
throughput production with limited screening)
Higher efficiency cloning of baculovirus constructs
Development Stage:
Prototype
Pilot
In vitro data available
Inventor: Dominic Esposito (NCI).
Intellectual Property: HHS Reference No. E-287-2012/0--Research
Tool. Patent protection is not being pursued for this technology.
Related Technology: HHS Reference No. E-164-2011--Combinatorial
Cloning Platform.
Licensing Contact: Susan Ano, Ph.D.; 301-435-5515;
[email protected].
Dated: July 9, 2013.
Richard U. Rodriguez,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. 2013-16947 Filed 7-15-13; 8:45 am]
BILLING CODE 4140-01-P